The Dispatch

FDA staff say Pfizer COVID vaccines safe and effective for small children

(Reuters) - U.S. Food and Drug Administration staff reviewers said Pfizer-BioNTech's COVID-19 vaccines were effective and safe for use in children aged 6 months to 4 years. The FDA reviewers said in briefing…

Read More Here

Pfizer says COVID treatment Paxlovid fails to prevent infection of household members

Pfizer Inc said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone infected with the virus.…

Read More Here

Demand for Pfizer’s COVID pills lags around the world

(Reuters) - Worldwide demand for Pfizer Inc’s oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a Reuters…

Read More Here

WHO backs Pfizer’s oral COVID therapy Paxlovid for high-risk patients

The World Health Organization (WHO) endorsed the use of Pfizer Inc's oral COVID-19 antiviral treatment in high-risk patients after an analysis of trial data by the U.N. agency showed the…

Read More Here

Pfizer COVID vaccine less effective in ages 5-11 -New York study

Two doses of the Pfizer Inc (PFE.N) and BioNTech SE (22UAy.DE) COVID-19 vaccine was protective against severe disease in children aged 5 to 11 during the recent Omicron variant surge,…

Read More Here

Updated: Pfizer COVID pill Paxlovid gets final approval from European Commission

Jan 28 (Reuters) - The European Commission on Friday approved Pfizer's antiviral pill for COVID-19 a day after the region's health regulator endorsed the tablet, a move that will ensure…

Read More Here

Pfizer and BioNTech launch trial of Omicron-targeted COVID vaccine

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which…

Read More Here

Pfizer CEO sees annual COVID vaccine rather than frequent boosters

Pfizer Inc Chief Executive Albert Bourla said that an annual COVID-19 vaccine would be preferable to more frequent booster shots in fighting the coronavirus pandemic. Pfizer/BioNtech's COVID-19 vaccine has shown…

Read More Here

Pfizer to boost COVID-19 pill production with French deal

PARIS, Jan 17 (Reuters) - Pfizer will add a production facility for its antiviral COVID-19 pill in France as part of a plan to invest 520 million euros ($594 million)…

Read More Here

Pfizer CEO: COVID virus will continue to circulate for many years

PARIS, Jan 17 (Reuters) - The chief executive of Pfizer told French TV station BFM TV on Monday that the coronavirus will continue to circulate for many years to come,…

Read More Here

Pfizer study shows COVID-19 booster can be given along with pneumonia shot

Jan 12 (Reuters) - Pfizer Inc said on Wednesday booster doses of its COVID-19 vaccine can be administered along with its pneumonia vaccine and produced strong safety and immune responses…

Read More Here

Britain approves Pfizer COVID-19 pill Paxlovid

Dec 31 (Reuters) - Britain has approved Pfizer's COVID-19 pill for patients over the age of 18 years who have mild to moderate infection and are at high risk of…

Read More Here

Israel orders Pfizer’s new COVID-19 pill

Israel has ordered 100,000 units of Pfizer Inc's anti-viral COVID 19 pill Paxlovid for people aged 12 and older at risk of severe illness, an Israeli official said, confirming a…

Read More Here

Pfizer oral COVID-19 pill gets U.S. authorization for at-home use

Dec 22 (Reuters) - Pfizer Inc said on Wednesday the U.S. Food and Drug Administration authorized its antiviral COVID-19 pill, making it the first at-home treatment for the coronavirus that…

Read More Here

Pfizer says COVID-19 pill near 90% protective against hospitalization, death

Pfizer Inc this week said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its…

Read More Here

EU to place order with Pfizer for COVID shots adapted to Omicron

European Union governments have agreed to exercise an option to buy more than 180 million doses of a version of the COVID-19 vaccine adapted for the Omicron variant developed by…

Read More Here

Pfizer says pandemic could extend to 2024

Pfizer Inc forecast that the COVID-19 pandemic would not be behind us until 2024 and said a lower-dose version of its vaccine for 2- to 4-year-olds generated a weaker immune…

Read More Here

Pfizer vaccine protecting against hospitalisation during Omicron wave – study

Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday,…

Read More Here

UPDATED: Study suggests Pfizer COVID-19 vaccine may only partially protect against Omicron

Omicron variant can partially evade protection from two doses of Pfizer and partner BioNTech's COVID-19 vaccine, the research head of a laboratory at the Africa Health Research Institute in South…

Read More Here

Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response – UK study

A major British study into mixing COVID-19 vaccines has found that people had a better immune response when they received a first dose of AstraZeneca or Pfizer-BioNTech shots followed by Moderna nine weeks…

Read More Here

UPDATED: UK study finds mRNA COVID-19 vaccines provide biggest booster impact

LONDON, Dec 3 (Reuters) - COVID-19 vaccines made by Pfizer and Moderna that use mRNA technology provide the biggest boost to antibody levels when given 10-12 weeks after the second…

Read More Here

Pfizer/BioNTech, Moderna expect data on shot’s protection against new COVID-19 variant soon

FRANKFURT, Nov 26 (Reuters) - BioNTech SE said on Friday it expects more data on a worrying new coronavirus variant detected in South Africa within two weeks to help determine…

Read More Here

UPDATED: EU drug regulator approves first COVID shot for 5-11 year olds

Nov 25 (Reuters) - The EU's drug regulator approved the use of Pfizer-BioNTech's COVID-19 vaccine for children between the ages of five and 11 on Thursday, paving the way for…

Read More Here

Pfizer sues departing employee it says stole COVID-19 vaccine secrets

Pfizer Inc has sued a longtime employee for allegedly stealing "scores" of confidential documents, including some related to its COVID-19 vaccine, as she prepared to jump to a competitor. In…

Read More Here

UPDATED: Pfizer’s COVID-19 vaccine shows long-term efficacy in trial in adolescents

Nov 22 (Reuters) - Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15…

Read More Here

EXPLAINER-All U.S. adults qualify for COVID-19 boosters; which is best?

CHICAGO, Nov 20 (Reuters) - The U.S. Centers for Disease Control and Prevention on Friday expanded availability of COVID-19 booster shots to all American adults, hoping to preserve vaccine protection…

Read More Here

EU advises on Merck COVID pill as reviews rival from Pfizer

The European Union's drug regulator has issued advice on using Merck's COVID-19 pill for adults and began a review of a rival tablet from Pfizer to help member states decide…

Read More Here

FDA authorizes Moderna and Pfizer’s COVID-19 vaccine booster for U.S. adults

Nov 19 (Reuters) - The U.S. Food and Drug Administration on Friday authorized booster doses of Pfizer Inc and BioNTech SE's COVID-19 vaccine for all adults, a move aimed at…

Read More Here

Pfizer to allow generic versions of its COVID-19 pill in 95 countries

Pfizer Inc said on Tuesday it will allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent…

Read More Here

UPDATED: Pfizer says antiviral pill cuts risk of severe COVID-19 by 89%

A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults…

Read More Here

Pfizer booster jab reduces risk of Covid hospitalisation by 93pc

Getting a Pfizer booster jab five months after a second dose reduces a person’s risk of hospitalisation with Covid by 93 per cent, according to new research in The Lancet.…

Read More Here

Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children

NEW YORK, Oct 21 (Reuters) - The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of five to 11 year olds, the U.S. drugmaker said…

Read More Here

Pfizer, BioNTech report high efficacy of COVID-19 booster shot in study

BERLIN, Oct 21 (Reuters) - Pfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their…

Read More Here

Pfizer vaccine very effective against Delta variant in adolescents in Israel – study

JERUSALEM, Oct 21 (Reuters) - The Pfizer/BioNTech COVID-19 vaccine is highly effective at preventing infection and symptomatic disease from the Delta variant among 12- to 18-year-olds, research conducted in Israel…

Read More Here

EU evaluating use of Pfizer’s COVID-19 vaccine in young children

Oct 18 (Reuters) - Europe's drug regulator said on Monday it was evaluating use of the Pfizer-BioNTech COVID-19 vaccine in children as young as five, while also taking steps to…

Read More Here

J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study

People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc /BioNTech SE or Moderna Inc,…

Read More Here

Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months, study shows

The effectiveness of the Pfizer Inc /BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second dose, according to data published on Monday…

Read More Here

Israel reports very few myocarditis heart inflammation cases after Pfizer boosters

Israel’s Health Ministry has identified fewer than 10 cases of heart inflammation following a third dose of the Pfizer/BioNtech vaccine among millions administered, according to recently released data. Israel began…

Read More Here

Pfizer begins study of oral drug for prevention of COVID-19

Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to…

Read More Here

EU drugs regulator to decide on Pfizer vaccine booster in early October

Sept 23 (Reuters) - The European Medicines Agency (EMA) aims to decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half…

Read More Here

Reports EU regulator to decide on Pfizer booster at the start of October

The European Medicines Agency (EMA) expects to decide in early October on the possible use of a booster dose of the Pfizer-BioNTech COVID-19 vaccine, a source with direct knowledge of…

Read More Here

U.S. decision on Pfizer COVID-19 shot for kids age 5-11 could come in October -sources

Sept 10 (Reuters) - Top U.S. health officials believe that Pfizer Inc's COVID-19 vaccine could be authorized for children aged 5-11 years old by the end of October, two sources…

Read More Here

U.S. COVID-19 booster shot campaign to start with only Pfizer – source

WASHINGTON, Sept 3 (Reuters) - A White House plan to offer COVID-19 booster shots will most likely start this month only with the vaccine made by Pfizer Inc and BioNTech…

Read More Here

UPDATED: New Zealand reports first death linked to Pfizer COVID-19 vaccine

New Zealand reported its first recorded death linked to U.S. drugmaker Pfizer's COVID-19 vaccine, the health ministry said on Monday, after a woman suffered a rare side effect leading to…

Read More Here

Pfizer vaccine safe in small study of very sick kids

In adolescents with serious neurological conditions, the side effects of the Pfizer/BioNTech vaccine are likely to be mild to moderate and clear up quickly, a small study suggests. The 27…

Read More Here

Third Pfizer dose 86% effective in over 60s, Israeli HMO says

A third dose of Pfizer /BioNTech's COVID-19 vaccine was found to be 86% effective in people aged over 60, an Israeli healthcare provider said on Wednesday, citing initial results from…

Read More Here

Pfizer, BioNtech submit data to FDA for COVID-19 vaccine booster authorization

(Reuters) - Pfizer Inc and German partner BioNtech SE have submitted initial data from an early stage trial to support application seeking authorization of a booster dose of their COVID-19…

Read More Here

Pfizer expands recall of anti-smoking drug Chantix over carcinogen presence

Pfizer Inc said it is recalling four additional lots of its anti-smoking treatment, Chantix, after finding elevated levels of cancer-causing agents called nitrosamines in the pills. In June, the drugmaker…

Read More Here

Israeli survey finds 3rd Pfizer vaccine dose has similar side effects to 2nd

Most people who received a third dose of Pfizer Inc's COVID-19 vaccine felt similar or fewer side effects than they did after receiving the second shot, according to an initial…

Read More Here

Tougher terms: why the EU is paying more for new COVID shots

The European Union has agreed to pay a premium on new orders of COVID-19 vaccines because it is requiring tougher terms to be met, European officials said, as the bloc tries to…

Read More Here

Pfizer and Moderna raise prices for COVID-19 vaccines in EU- FT

(Reuters) -Pfizer Inc and Moderna Inc have raised the prices of their COVID-19 vaccines in their latest European Union supply contracts, the Financial Times reported on Sunday. The new price…

Read More Here

UPDATED: Israel to offer third shot of Pfizer vaccine to people over 60

Israel will begin offering a third shot of the Pfizer/Biontech COVID-19 vaccine to people aged over 60, a world first in efforts to slow the spread of the highly contagious…

Read More Here

Mixed AstraZeneca-Pfizer shot boosts COVID antibody level – study

A mixed vaccination of first AstraZeneca and then a Pfizer COVID-19 shot boosted neutralizing antibody levels by six times compared with two AstraZeneca doses, a study from South Korea showed.…

Read More Here

Australia’s drug regulator approves Pfizer COVID-19 vaccine for 12 to 15-year-olds

Australia's drug regulator has approved Pfizer's COVID-19 vaccine for use with 12 to 15-year-olds, Federal Health Minister Greg Hunt said on Friday, as the country fights an outbreak of the…

Read More Here

Spacing Pfizer COVID shots boosts antibody levels after initial drop -study

A longer gap between doses of Pfizer's COVID-19 vaccine leads to higher overall antibody levels than a shorter gap, a British study found on Friday, but there is a sharp…

Read More Here

Two doses of Pfizer, AstraZeneca shots effective against Delta variant, study finds

Two doses of Pfizer or AstraZeneca's COVID-19 vaccine are nearly as effective against the highly transmissible Delta coronavirus variant as they are against the previously dominant Alpha variant, a study…

Read More Here

Israel offers third shot of Pfizer COVID-19 vaccine to adults at risk

Israel said on Sunday it will begin offering a third dose of Pfizer Inc's vaccine to adults with weak immune systems but it was still weighing whether to make the…

Read More Here